{"title":"奥马珠单抗与鼻腔过敏治疗","authors":"Ö. Özdemir","doi":"10.15406/MOJI.2018.06.00187","DOIUrl":null,"url":null,"abstract":"Omalizumab is an anti-human IgE humanized monoclonal antibody produced against CƐ3 domain of the Fc fragment of IgE molecule. Omalizumab suppresses the effector roles of IgE by preventing binding to high-affinity receptors (FcεR1) on allergy-related immune effector cells and blocking mast cell or basophil mediator release.4 Based on this mechanism of action, Omab also provides symptomatic relief to allergic patients.","PeriodicalId":90928,"journal":{"name":"MOJ immunology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Omalizumab and sino-nasal allergy treatment\",\"authors\":\"Ö. Özdemir\",\"doi\":\"10.15406/MOJI.2018.06.00187\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Omalizumab is an anti-human IgE humanized monoclonal antibody produced against CƐ3 domain of the Fc fragment of IgE molecule. Omalizumab suppresses the effector roles of IgE by preventing binding to high-affinity receptors (FcεR1) on allergy-related immune effector cells and blocking mast cell or basophil mediator release.4 Based on this mechanism of action, Omab also provides symptomatic relief to allergic patients.\",\"PeriodicalId\":90928,\"journal\":{\"name\":\"MOJ immunology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"MOJ immunology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/MOJI.2018.06.00187\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"MOJ immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/MOJI.2018.06.00187","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Omalizumab is an anti-human IgE humanized monoclonal antibody produced against CƐ3 domain of the Fc fragment of IgE molecule. Omalizumab suppresses the effector roles of IgE by preventing binding to high-affinity receptors (FcεR1) on allergy-related immune effector cells and blocking mast cell or basophil mediator release.4 Based on this mechanism of action, Omab also provides symptomatic relief to allergic patients.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
